Skip to content

Huabiao Chen, PhD

Principal Investigator

Dr. Chen joined VIC in 2015 with a focus on mesenchymal stem/stromal cells (MSCs) and MSC-derived intracellular vesicles/exosomes for therapy of various cancers. He is actively involved in the preclinical development of vaccines and immunotherapies for cancer by regrouping and redirecting immune responses in the tumor microenvironment to combat cancer.

Dr. Chen is also involved in infectious disease research, particularly in HIV/AIDS, leading an effort in investigation of immune responses by which some remarkable HIV-1-infected individuals are able to persistently control HIV-1 replication without medications (named elite controllers) that will help the design of therapeutic strategies against HIV-1 infection and defining the relevant immunogens for an effective AIDS vaccine.

Prior Experience

Dr. Chen worked at the Howard Hughes Medical Institute (HHMI) from 2007- 2012 as a Research Specialist and then at the Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University from 2012 to 2015 as a Senior Research Scientist. He was awarded the Young Scientist Award of Global HIV Vaccine Enterprise in 2010.

Outside of VIC

He serves on the grant review board for the DOD Ovarian Cancer Research Program, the DOD Peer Reviewed Cancer Research Program, and the NIH IDeA Network of Biomedical Research Excellence (INBRE) Program.

Academic Credentials